Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of September 2024, specifically dated September 24, 2024. The report serves to disseminate a press release regarding the publication of 5-year trial results for the Company's ProSense cryoablation system in the peer-reviewed Annals of Surgical Oncology journal.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on clinical trial outcomes rather than financial performance.
Material Changes and Clinical Results
The primary material update concerns the ICE3 5-Year Trial results for early-stage, low-risk breast cancer treated with ProSense cryoablation without excision. Key findings include:
- Recurrence Free Rate: The trial demonstrated a 96.3% recurrence-free rate over a 5-year period.
- Publication: Results were published in the Annals of Surgical Oncology.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the attached press release (Exhibit 99.1) by reference into the Company's Registration Statements on Form F-3 and Form S-8. The text does not explicitly detail specific financial guidance, management commentary on operations, or a list of risks within the body of this Form 6-K, deferring to the incorporated press release for such details.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed methodology and limitations of the ICE3 trial.
- Review the "Forward Looking Statements" section in the press release for specific risks associated with the commercialization of these results.
- Confirm the impact of these clinical results on regulatory approval timelines and market adoption strategies.
- Check subsequent filings for any financial updates or changes in capitalization resulting from this news.